2019 has been an excellent year in terms of peptides and oligonucleotides (TIDES) approved by the FDA. Despite the drop in the number of total drugs approved by the FDA in 2019 in comparison with 2018 (48 vs. 59), the total number of TIDES authorized increased (seven vs. three). Year after year, TIDES are increasingly present in therapy, as imaging agents, theragnostic and constituent moieties of other complex drugs, such as antibody drug conjugates. This means a consolidation of these kinds of drugs in the pharmaceutical arena, paving the way in the coming years for the approval of others for diverse medical indications. Here the TIDES approved in 2019 are analyzed in terms of chemical structure, medical target, mode of action, and adverse effects.
Danah Al Shaer, Othman Al Musaimi, Fernando Albericio, and Beatriz G. de la Torre
Pharmaceuticals, Vol 12, Iss 2, p 52 (2019)
dotatate, drugs, inotersen, Lutathera, oligonucleotides, Onpattro, patisiran, peptides, pharmaceutical market, Tegsedi, Pharmacy and materia medica, and RS1-441
In 2018, the United States Food and Drug Administration (FDA) approved a total of 59 new drugs, three of them (5%) are TIDES (or also, -tides), two oligonucleotides and one peptide. Herein, the three TIDES approved are analyzed in terms of medical target, mode of action, chemical structure, and economics.
Othman Al Musaimi, Danah Al Shaer, Beatriz G. de la Torre, and Fernando Albericio
Pharmaceuticals, Vol 11, Iss 2, p 42 (2018)
pharmaceutical market, drugs, drug discovery, solid-phase peptide synthesis, Pharmacy and materia medica, and RS1-441
2017 was an excellent year in terms of new drugs (chemical entities and biologics) approved by the FDA, with a total of 46. In turn, one of the highlights was the number of peptides (six) included in this list. Here, the six peptides are analyzed in terms of chemical structure, synthetic strategy used for their production, source, therapeutic use, and mode of action.